Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Teucrium Wheat Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Teucrium Wheat Fund trades at $22.85. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| ACAD | WEAT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $25.49 |
52-Week Low | $20.06 | $19.88 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
WEAT (Teucrium Wheat Fund) trades at $22.93, up 2.32% today, while technical indicators signal a bearish trend with moving averages showing sell pressure. The fund faces headwinds from reduced USDA wheat production forecasts and inflation concerns. Key support sits at $22 with resistance at $23, creating a tight trading range amid neutral oscillator readings.
Outlook remains cautious given agricultural commodity volatility and macroeconomic pressures. Investment opportunity exists for hedging against inflation, but risks include weather-dependent production and Federal Reserve policy impacts on commodity prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
